{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:32:17Z","timestamp":1782732737063,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ijgc-2023-004781","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:49:12Z","timestamp":1704847752000},"page":"239-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5588-7441","authenticated-orcid":false,"given":"Anneke","family":"Westermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn G H","family":"Van Oijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9752-0947","authenticated-orcid":false,"given":"Roy","family":"Lalisang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella O","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004781_bb0010","author":"World Health Organization","year":"2018","journal-title":"GLOBOCAN 2018: estimated cancer incidence, mortality and prevalence worldwide in 2018"},{"key":"10.1136\/ijgc-2023-004781_bb0015","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999\u20132007: results of the EUROCARE-5 study","volume":"51","author":"Sant","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004781_bb0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: a systematic review","volume":"17","author":"Decruze","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004781_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2022.10.012","article-title":"Looking beyond carboplatin and paclitaxel for the treatment of advanced\/recurrent endometrial cancer","volume":"167","author":"Rubinstein","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1136\/ijgc-2023-004781_bb0045","first-page":"1","article-title":"Review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2023-004781_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004781_bb0055","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004781_bb0060","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or Ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004781_bb0075","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"PK-PD correlation from mouse to human with pazopanib, a multi-kinase angiogenesis inhibitor with potent antitumour and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2023-004781_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2023-004781_bb0085","first-page":"410","article-title":"An impressive response to pazopanib in a patient with metastatic endometrial carcinoma","volume":"74","author":"van der Steen","year":"2016","journal-title":"Neth J Med"},{"key":"10.1136\/ijgc-2023-004781_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2019.04.044","article-title":"Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamics characterization from GARNET, a phase I\/II clinical trial of the anti\u2013PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer","volume":"154","author":"Oaknin","year":"2019","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24221599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:12:29Z","timestamp":1761844349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24221599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1048891X24221599"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004781","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}